MobileODT, a Tel Aviv, Israel-based developer of the EVA System for cervical cancer screening, closed a $4m Series C funding round.
The round, which has raised $26m in total funding to date, was led by OrbiMed Israel Partners, with participation from Tristel, Tara Health and Laerdal.
The company intends to use the funds to further develop AI (Augmented Intelligence) clinical decision support technology for the evaluation of cervical cancer at the point of care.
Led by newly appointed CEO Leon A. Boston, MobileODT helps clinicians utilize AI on its portable medical devices to enhance women’s health. Its EVA System combines advanced imaging, data and software applications, to expand access to quality care in 30 countries and across more than 60 US health systems. The EVA System’s smart mobile colposcope is used by clinicians worldwide for colposcopy, general gynecology, telegynecology, and forensic imaging. The company is integrating its AI in approved markets to provide clinical decision support to healthcare providers at the point-of-care.